Trials / Completed
CompletedNCT01358825
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™
Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 5 Years – 6 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.
Conditions
- Tetanus
- Poliomyelitis
- Haemophilus Influenzae Type b
- Acellular Pertussis
- Diphtheria
- Hepatitis B
- Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood Sampling | A blood sample will be taken at 5 years of age, after vaccination in the primary study. |
Timeline
- Start date
- 2011-05-30
- Primary completion
- 2011-07-15
- Completion
- 2011-07-15
- First posted
- 2011-05-24
- Last updated
- 2021-01-19
- Results posted
- 2016-12-29
Locations
4 sites across 2 countries: Norway, Sweden
Source: ClinicalTrials.gov record NCT01358825. Inclusion in this directory is not an endorsement.